November 1, 2021Panminerva Medica
Pharmacologic treatment of acute and recurrent pericarditis: a systematic review and meta-analysis of controlled clinical trials
Why the study?
Recurrence is the most frequent complication following acute pericarditis, prompting an evaluation of the efficacy of various pharmacological treatments for acute and recurrent pericarditis.
Do pharmacological treatments such as colchicine and anti-interleukin-1 agents reduce the risk of recurrent pericarditis in patients with acute or recurrent pericarditis?
Comparison
Pharmacological treatments (colchicine, anti-IL-1 agents) vs standard treatment or placebo
Design
Systematic review and meta-analysis of randomized controlled trials
Authors
Discussion
Loading...
Member takes
Implication
Supports colchicine and anti-IL-1 agents for pericarditis recurrence prevention; reinforces RCT evidence for updated guidelines.
Structured PICO
Do pharmacological treatments such as colchicine and anti-interleukin-1 agents reduce the risk of recurrent pericarditis in patients with acute or recurrent pericarditis?
P
Population
11 RCTs of patients with acute pericarditis, recurrent pericarditis, or post-pericardiotomy syndrome
I
Intervention
Pharmacological treatments including colchicine (9 RCTs) or anti-interleukin-1 agents (anakinra, rilonacept) (2 RCTs)
C
Comparator
Standard treatment or placebo
O
Outcome
Recurrent pericarditishard clinical
Colchicine and anti-interleukin-1 agents are highly effective in reducing the risk of recurrent pericarditis compared to standard therapy or placebo.
Cite This Study
Avondo et al. (2021) studied this question.